poisar

Stocks · News reference

Alfasigma Announces GSK Presentations on Linerixibat at AASLD The Liver Meeting 2026

Fiscal.ai

Alfasigma announced that GSK will present five studies on linerixibat for primary biliary cholangitis (PBC) at the upcoming AASLD The Liver Meeting 2026.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Fiscal.ai

    Berenberg Maintains 'Buy' Rating on GSK

    Berenberg has reaffirmed its 'Buy' rating on GSK with a price target of 2200 pence, following the company's third-quarter financial results.